Vai Yunnan Baiyao Group Co dividende ir droša?
Yunnan Baiyao Group Co palielina dividendes jau 1 gadus.
Pēdējo 10 gadu laikā Yunnan Baiyao Group Co ir paaugstināts to par 21,642 % gadā.
Pēdējo piecu gadu laikā izmaksas palielinājās par 7,245 %.
Analisti prognozē, ka šajā tekošajā finanšu gadā gaidāms Dividendu samazināšana aptuveni -0,595%.
Yunnan Baiyao Group Co Aktienanalyse
Ko dara Yunnan Baiyao Group Co?
Yunnan Baiyao Group Co Ltd is a Chinese company that has been in existence since 1902 and is now one of the most well-known and largest healthcare companies in China. The company is headquartered in the city of Kunming in Yunnan province in southwest China.
The company's history began when a Red Cross crusader named Qu Huanzhang from Belgium came to China in 1902. He founded a small herbal medicine clinic in Yunnan to treat local patients. There, he soon developed a herbal medicine called Yunnan Baiyao.
As the company grew over the years, it added more products based on traditional Chinese healing methods. Today, Yunnan Baiyao Group Co Ltd is an integrated company specializing in a variety of healthcare fields, from manufacturing medicines to biotechnology.
The company's business model is focused on meeting consumers' needs for health and well-being. The company strives to develop and provide high-quality and innovative products and services to ensure that its customers' needs are met.
Yunnan Baiyao Group Co Ltd has established itself in various sectors of the healthcare industry. The company's main divisions are pharmaceutical products, biomedical products, health and wellness products, and medical devices.
The most well-known product of Yunnan Baiyao Group Co Ltd is Yunnan Baiyao Powder, which is made from over 20 different herbal ingredients. It is traditionally used to treat wounds, injuries, bleeding, and internal organ diseases, and is often prescribed by Chinese doctors.
Yunnan Baiyao Group Co Ltd also produces medications for infectious diseases, cardiovascular diseases, cancer, and other illnesses. The company is committed to conducting innovative research and development to ensure the effectiveness and safety of the products it manufactures.
In addition to pharmaceutical products, the company also offers biomedical products focusing on the research and development of immunotherapies for the treatment of cancer and other diseases. Yunnan Baiyao Group Co Ltd also has a product portfolio in the health and wellness products sector, including dietary supplements and herbal teas.
The company has also developed medical devices, including diagnostic and monitoring devices for intensive care and hospital care.
In recent years, Yunnan Baiyao Group Co Ltd has focused heavily on international expansion and now has branches in the United States, Europe, and Hong Kong. It has also formed partnerships with international healthcare companies to strengthen its presence in global markets.
Overall, Yunnan Baiyao Group Co Ltd has established itself as a leading healthcare company in China based on traditional Chinese healing methods while also conducting innovative scientific research and development. The company is committed to providing high-quality products and services to improve the health and well-being of its customers. Yunnan Baiyao Group Co ir viens no populārākajiem uzņēmumiem vietnē Eulerpool.com.Akcienu ieguldījumu plāni piedāvā investoriem pievilcīgu iespēju ilgtermiņā uzkrāt kapitālu. Viens no galvenajiem priekšrocībām ir tā sauktais Vidējās izmaksas efekts: ieguldot regulāri noteiktu summu akcijās vai akciju fondos, automātiski tiek iegādāts vairāk daļu, kad cenas ir zemas, un mazāk, kad tās ir augstas. Tas laika gaitā var novest pie izdevīgākas vidējās cenas par daļu. Turklāt akcienu ieguldījumu plāni nodrošina piekļuvi dārgām akcijām arī mazajiem investoriem, jo tiem var pievienoties jau ar nelielām summu. Regulāra ieguldījumu veikšana arī veicina disciplinētu ieguldījumu stratēģiju un palīdz izvairīties no emocionāliem lēmumiem, piemēram, impulsīvas pirkšanas vai pārdošanas. Turklāt investori gūst labumu no potenciālās akciju vērtības pieauguma un no dividendēm, kuras var reinvestēt, tādejādi pastiprinot procentu uz procentu efektu un līdz ar to investētā kapitāla augšanu.